epratuzumab

As nouns the difference between terms and epratuzumab

is that terms is while epratuzumab is a humanized monoclonal antibody with potential applications in oncology and in the treatment of inflammatory autoimmune disorders such as lupus.

As a noun epratuzumab is

a humanized monoclonal antibody with potential applications in oncology and in the treatment of inflammatory autoimmune disorders such as lupus.

As nouns the difference between disorder and epratuzumab

is that disorder is absence of order; state of not being arranged in an orderly manner while epratuzumab is a humanized monoclonal antibody with potential applications in oncology and in the treatment of inflammatory autoimmune disorders such as lupus.

As an adjective autoimmune

is of or pertaining to autoimmunity.

As a noun epratuzumab is

a humanized monoclonal antibody with potential applications in oncology and in the treatment of inflammatory autoimmune disorders such as lupus.

As nouns the difference between inflammatory and epratuzumab

is that inflammatory is any material that causes inflammation while epratuzumab is a humanized monoclonal antibody with potential applications in oncology and in the treatment of inflammatory autoimmune disorders such as lupus.

As an adjective inflammatory

is tending to inflame or provoke somebody.

As nouns the difference between oncology and epratuzumab

is that oncology is the branch of medicine concerned with tumors, including study of their development, diagnosis, treatment, and prevention while epratuzumab is a humanized monoclonal antibody with potential applications in oncology and in the treatment of inflammatory autoimmune disorders such as lupus.

As a verb humanized

is (humanize).

As a noun epratuzumab is

a humanized monoclonal antibody with potential applications in oncology and in the treatment of inflammatory autoimmune disorders such as lupus.